Children with other conditions can be more at risk for severe infection from influenza.
In a study now on online in the prestigious British Medical Journal, researchers examined pediatric cases from dozens of emergency departments in hospitals around the world during the global influenza pandemic of 2009. The results enabled the team to pinpoint several clinical risk factors for severe infections in youngsters who arrive at a hospital with influenza-like illnesses due to H1N1 infections. The information would be invaluable during a pandemic, when emergency departments and primary-care facilities experience large surges of young patients who arrive with flu-like symptoms.
The study, which assessed each patient’s clinical history and physical examination, identified the following predictors of severe H1N1 infection and potentially fatal outcomes in children:
- History of chronic lung disease
- History of cerebral palsy/developmental delay
- Signs of chest retractions (difficulty breathing)
- Signs of dehydration
- Requires oxygen to keep blood levels normal
- Heart rate that exceeds normal range (tachycardia) relative to age
“The basic question clinicians face when they are in the middle of an influenza epidemic like H1N1 is whether their patient is at risk of severe complications,” said Stuart Dalziel, lead author of the study and a pediatrician at New Zealand’s Starship Children’s Hospital and The University of Auckland, and vice-chair of the Paediatric Research in Emergency Departments International Collaborative (PREDICT) network. “One of the key strengths of this study is that it provides clinicians with meaningful and more precise information that can enable them to identify those children with fever and flu-like symptoms who are at greater risk of severe complications.”
The findings stem from 265 pediatric cases culled from 79 emergency departments of hospitals associated with the Pediatric Emergency Research Networks (PERN) in 12 countries.
“Having a more accurate idea of what to look for in pediatric cases, especially during a pandemic, would be especially important to clinicians because it provides crucial guidance for those who would be trying to direct the appropriate levels of treatment for many patients in a short time,” said Nathan Kuppermann, professor and chair of emergency medicine at the University of California, Davis, one of the study’s senior authors and a principal investigator in the Pediatric Emergency Care Applied Research Network (PECARN).
Because of its unparalleled global network of hospitals and patient data, the PERN study also added weight to the efficacy and use of the anti-viral drug oseltamivir (trade name Tamiflu) to treat the children with H1N1 influenza virus infections to reduce the severity of infection. Researchers noted there was good evidence of an association between oseltamivir treatment and a reduced frequency of death in children admitted to an intensive care unit for assisted ventilation.
“This study shows the incredible power of PERN, bringing together five pediatric emergency research networks and many emergency departments from around the world, to produce this very significant study which has the power to identify the most at-risk children in a future influenza pandemic,” said Terry P. Klassen, the study’s senior author, CEO and scientific director at the Manitoba Institute of Child Health in Canada and a site investigator with Pediatric Emergency Research Canada (PERC).
The global research collaborative is comprised of the five major pediatric networks, which are located in Europe and the Middle East (Research in European Paediatric Emergency Medicine, or REPEM), North America (PECARN, PERC and the Pediatric Emergency Medicine Collaborative Research Committee), and in Australia and New Zealand (PREDICT). Together, the five networks have access to data from more than three million pediatric emergency department cases annually from more than 100 hospitals, which are located in four of the six World Health Organization (WHO) regions.
Other study authors: John M.D. Thompson, senior research fellow, University of Auckland; Charles G. Macias, associate professor, Baylor College of Medicine and Texas Children’s Hospital; Ricardo M. Fernandes, pediatrician, Hospital de Santa Maria, Portugal; David W. Johnson, professor at Canada’s Children’s Hospital Research Institute, Calgary; Yehezkel Waisman, professor, Schneider Children’s Medical Center of Israel; Nicholas Cheng, pediatrician, Children’s Hospital, Westmead, Australia; Jason Acworth, pediatrician, Royal Children’s Hospital, Australia; James M. Chamberlain, professor, Children’s National Medical Center, Washington, D.C.; Martin H. Osmond, professor, and Amy Plint, associate professor, University of Ottawa and Children’s Hospital of Eastern Ontario, Canada; Paolo Valerio, pediatrician, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands; Karen J.L. Black, pediatrician, and Eleanor Fitzpatrick, research coordinator, IWK Health Centre, Halifax, Canada; Amanda S. Newton, assistant professor, University of Alberta, Canada.
Funding: PECARN is supported by HRSA/MCHB/EMSC through the following cooperative agreements: U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008, U03MC22684, and U03MC22685. Stuart Dalziel is supported by the Health Research Council of New Zealand. John M.D. Thompson received funding from the Logan Campbell Trust, Auckland, New Zealand, to attend an investigator meeting, with time funded by CureKids, New Zealand. Investigators’ time was funded by their host institutions and/or research networks. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.